| Young June Choe | 9 Articles |
Objectives
This study aimed to assess the impact of high-level versus low-level construal messages about the coronavirus disease 2019 (COVID-19) Vaccine Injury Compensation Program (CVICP) on public attitudes toward the program and COVID-19 vaccination. Methods A randomized controlled experimental design was employed. Adults aged 18 to 64 residing in the Republic of Korea were randomly assigned to either an experimental group (high-level construal message) or a control group (low-level construal message). Both groups viewed a 2-minute video about the CVICP, with construal level as the sole variable. Pre- and post-intervention questionnaires evaluated attitudes toward the CVICP and COVID-19 vaccination, including satisfaction, perceived necessity, and perceived effectiveness in enhancing vaccine acceptance. Data were analyzed using the paired t-test, repeated measures 2-way analysis of variance, and multiple linear regression. Results The experimental group showed statistically significant improvements across all 6 attitude measures following exposure to the high-level construal message. By contrast, the control group demonstrated significant improvement in only 3 attitudes: satisfaction with the CVICP, willingness to recommend vaccination, and willingness for future vaccination. A significant difference between groups was observed for perceived effectiveness of the CVICP in enhancing vaccine acceptance (p=0.01), with high-level construal messaging being more impactful. Conclusion High-level construal messages are more effective than low-level messages in shaping public perceptions and addressing vaccine hesitancy. Policymakers and health authorities should incorporate high-level construal elements into communication strategies to build trust and support for vaccination programs.
Objectives
Subacute sclerosing panencephalitis (SSPE) is a rare but fatal neurodegenerative disease caused by persistent measles virus infection. After a significant measles outbreak in 2000–2001, the Republic of Korea implemented a nationwide measles elimination program, which led to a dramatic reduction in measles incidence. This study aimed to evaluate the impact of these measles elimination efforts on the incidence of SSPE in the Republic of Korea. Methods This nationwide, population-based retrospective cohort study identified patients newly diagnosed with measles and SSPE between 2007 and 2022, registered in the Health Insurance Review and Assessment Service (HIRA) and Korea Disease Control and Prevention Agency (KDCA) databases. Population-based incidence rates of measles and SSPE were calculated and compared annually. Results A total of 236 measles cases (HIRA data) and 1,168 measles cases (KDCA data), along with 2,736 SSPE cases, were diagnosed during the study period. Measles incidence significantly declined, reaching zero cases in 2021, while SSPE incidence displayed an upward trend, peaking in 2014. The mean age at SSPE onset was 21.2 years, with a marked male-to-female ratio of 13.0:1. Conclusion SSPE incidence was remarkably low in the post-outbreak period, likely attributable to successful measles control. This study underscores the critical importance of maintaining low measles incidence through sustained vaccination efforts, preventing SSPE and other measles-related complications. Citations
Citations to this article as recorded by
This study aimed to establish a foundation for future collaborations aimed at preparing for and responding to infectious diseases by examining the vaccine injury compensation programs (VICPs) of East Asian countries. We reviewed the current status of VICPs in the Republic of Korea, Japan, and Taiwan by searching national government websites and reviewing relevant literature. Additionally, we conducted email inquiries targeting experts from Japan and Taiwan. Through the comprehensive analysis of VICPs in these 3 countries covered various aspects, we identified several similarities and differences in the VICPs across these countries. While the governments of the Republic of Korea, Japan, and Taiwan play a central role in supporting investigations into vaccine injuries and managing compensation procedures based on legal statutes, they differ in terms of financial resources for compensation, the range of vaccines covered, and the criteria for assessing causality. In the Republic of Korea, Japan, and Taiwan, compensation is typically paid in a lump sum, although the specific benefits available vary by country. This study on VICPs in the Republic of Korea, Japan, and Taiwan provides valuable insights for the further development and management of domestic systems.
Citations
Citations to this article as recorded by
Objectives
This study aimed to comprehensively outline the methodological approaches used in published research comparing the vaccine effectiveness (VE) of coronavirus disease 2019 (COVID-19) vaccines. Methods A systematic search was conducted on June 13, 2024, to identify comparative studies evaluating the effectiveness of mRNA versus non-mRNA and monovalent versus bivalent COVID-19 vaccines. We screened titles, abstracts, and full texts, collecting data on publication year, country, sample size, study population composition, study design, VE estimates, outcomes, and covariates. Studies that reported relative VE (rVE) were analyzed separately from those that did not. Results We identified 25 articles comparing rVE between mRNA and non-mRNA COVID-19 vaccines, as well as between monovalent and bivalent formulations. Among the studies assessing VE by vaccine type, 126 did not provide rVE estimates. Comparative VE studies frequently employed retrospective cohort designs. Among the definitions of rVE used, the most common were hazard ratio and absolute VE, calculated as (1−odds ratio)×100. Studies were most frequently conducted in the United Kingdom and the United States, and the most common outcome was infection. Most targeted the general population and assessed the VE of mRNA vaccines using the AstraZeneca vaccine as a reference. A small proportion, 7.3% (n=11), did not adjust for any variables. Only 3 studies (2.0%) adjusted for all core confounding variables recommended by the World Health Organization. Conclusion Few comparative studies of COVID-19 vaccines have incorporated rVE methodologies. Reporting rVE and employing a consistent set of covariates can broaden our understanding of COVID-19 vaccines. Citations
Citations to this article as recorded by
Objectives
We estimated the overall and age-specific percentages of the Korean population with presumed immunity against severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) as of April 2022 using the national registry. Methods We used the national coronavirus disease 2019 (COVID-19) infection and vaccination registry from South Korea, as described to define individuals with a previous history of COVID-19 infection, vaccination, or both, as persons with presumed immunity. Results Of a total of 53,304,627 observed persons, 24.4% had vaccination and infection, 58.1% had vaccination and no infection, 7.6% had infection and no vaccination, and 9.9% had no immunity. The SARS-CoV-2 Omicron variant emerged at a time when the presumed population immunity ranged from 80% to 85%; however, nearly half of the children were presumed to have no immunity. Conclusion We report a gap in population immunity, with lower presumed protection in children than in adults. The approach presented in this work can provide valuable informed tools to assist vaccine policy-making at a national level. Citations
Citations to this article as recorded by
<p>A substantial, immediate healthcare burden for screening of Coronavirus disease 2019 (COVID-19) is created when large-scale outbreaks occur. There have been a series of measures to strengthen the screening process through robust public-private partnerships between Hanam City Public Health Center (PHC), the local medical association, and central/provincial government. A partnership between PHC and the local physician’s group in Hanam City established the Respiratory Clinic. The PHC provided the infrastructure for the Respiratory Clinic including medical facilities, supplies (i.e. personal protective equipment), and administrative support. A total of 11 registered physicians from the local physicians group agreed to participate in clinical service provided at the Respiratory Clinic. Any citizens with COVID-19 suspected respiratory symptoms call the COVID-19 hotline and visit the Respiratory Clinic if required. Responding to COVID-19 outbreaks will be a continual process, and the screening system is essential support to public health interventions, and crucial in the response to a surge in COVID-19 cases.</p>
Citations
Citations to this article as recorded by
Citations
Citations to this article as recorded by
The Division of Vaccine-Preventable Disease Control and National Immunization Program of the Korea Centers for Disease Control and Prevention has prepared a plan of action as a guide for key actions that will be taken if a poliovirus outbreak occurs in the Republic of Korea. The history of poliomyelitis and vaccination against poliovirus in the nation was reviewed and the routine surveillance procedures that are currently in place were described. The principles and specific actions for an effective response to a poliovirus outbreak were prepared. The guidelines clearly outline the actions to be taken in case of a polio outbreak. When a suspected case of poliovirus infection is reported, an immediate epidemiological investigation is to be conducted. The response to a poliovirus outbreak includes case isolation, management of potential contacts and immunization. All stakeholders are to be made aware of what key actions should be taken at each stage of the response to a poliovirus outbreak in the nation.
Citations
Citations to this article as recorded by
Objectives
The aim of this study was to review the epidemiologic data of rubella and congenital rubella syndrome (CRS) supplied by surveillance systems from 2001 to 2009 and to propose measures to improve the quality of the surveillance system in the Republic of Korea. Methods The epidemiological data for rubella and CRS cases reported to the Korea Centers for Disease Control and Prevention from 2001 to 2009 were retrospectively reviewed, and insurance reimbursement data from the Korea National Health Insurance Review Agency were collected for comparison. Results The number of yearly reported rubella cases to the Korea Centers for Disease Control and Prevention from 2001 to 2009 was 128, 24, 8, 24, 15, 12, 35, 30, and 36, respectively. The occurrence of rubella shifted to a slightly higher age group during the 9-year period, i.e. from 0–9 years to 10–19 years. Among the 309 reported rubella cases, three were confirmed cases of CRS. In addition, according to data sourced from Health Insurance Review Agency, 24, 19, 19, 9, and 5 CRS cases were reported for medical insurance reimbursement from 2005 to 2009, respectively. Conclusion According to available surveillance data, the reported cases of rubella and CRS were not high, but a more detailed surveillance with emphasis on susceptible women of childbearing age is necessary for better monitoring and control of rubella and CRS in the Republic of Korea. Citations
Citations to this article as recorded by
|
|
